GRI
GRI Bio, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.20
P/S
0.01
EV/EBITDA
0.66
DCF Value
$65.24
FCF Yield
-4706.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-0.0%
Operating Margin
-41.5%
Net Margin
-41.4%
ROE
-381.7%
ROA
-138.0%
ROIC
-197.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-2.7M | $-5.34 |
| Q4 2025 | $0.00 | $-2.7M | $-5.34 |
| FY 2025 | $0.00 | $-12.0M | $-121.80 |
| Q3 2025 | $6.3M | $-3.4M | $-35.84 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-1.24
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.